Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXER1 | Q8TDS5 | 4/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.73 |
| ▸ | PPARG | P37231 | 5/20 | 0.73 |
| ▸ | PPARD | Q03181 | 4/20 | 0.73 |
| ▸ | PPARA | Q07869 | 4/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.73 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.73 |
| ▸ | FABP4 | P15090 | 2/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.73 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.73 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | USP2 | O75604 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3411105 | 0.94 | OXER1 (0.73) | OXER1ALDH1A1PPARGPPARDPPARA | |
| SCHEMBL25395595 | 0.94 | OXER1 (0.72) | OXER1ALDH1A1PPARGPPARDPPARA | |
| SCHEMBL38655167 | 0.91 | PPARG (0.72) | OXER1ALDH1A1PPARGPPARDPPARA | |
| SCHEMBL1242004 | 0.90 | OXER1 (1.00) | OXER1ALDH1A1PPARGPPARDPPARA | |
| SCHEMBL1479341 | 0.90 | OXER1 (0.95) | OXER1ALDH1A1PPARGPPARDPPARA | |
| SCHEMBL16670813 | 0.90 | OXER1 (1.00) | OXER1ALDH1A1PPARGPPARDPPARA | |
| SCHEMBL1476445 | 0.90 | OXER1 (1.00) | OXER1ALDH1A1PPARGPPARDPPARA | |
| SCHEMBL22607964 | 0.90 | OXER1 (1.00) | OXER1ALDH1A1PPARGPPARDPPARA | |
| SCHEMBL21214020 | 0.90 | OXER1 (1.00) | OXER1ALDH1A1PPARGPPARDPPARA | |
| SCHEMBL7718095 | 0.90 | OXER1 (0.95) | OXER1ALDH1A1PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160256521-A1 | TOPICAL FORMULATIONS AND USES THEREOF | OCULAR TECHNOLOGIES SARL (CH) | 2016-09-08 | — | — | US | disclosed |
| US-20160256521-A1 | TOPICAL FORMULATIONS AND USES THEREOF | OCULAR TECHNOLOGIES SARL (CH) | 2016-09-08 | — | — | US | disclosed |
| US-9315447-B2 | Compositions and methods for the treatment of inflammation | A.T. Resolve Sarl (CH) | 2016-04-19 | — | — | US | disclosed |
| US-9315447-B2 | Compositions and methods for the treatment of inflammation | A.T. Resolve Sarl (CH) | 2016-04-19 | — | — | US | disclosed |
| EP-2419399-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | C T RESOLVE SARL (CH) | 2016-03-23 | — | — | EP | disclosed |
| US-20150165048-A1 | TOPICAL FORMULATIONS AND USES THEREOF | SUN PHARMA GLOBAL FZE (AE) | 2015-06-18 | — | — | US | disclosed |
| US-20150165048-A1 | TOPICAL FORMULATIONS AND USES THEREOF | SUN PHARMA GLOBAL FZE (AE) | 2015-06-18 | — | — | US | disclosed |
| US-20140275247-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | A.T. Resolve Sarl (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140275247-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | A.T. Resolve Sarl (CH) | 2014-09-18 | — | — | US | disclosed |
| US-8673881-B2 | Compositions and methods for the treatment of inflammation | A.T. Resolve Sarl (CH) | 2014-03-18 | — | — | US | disclosed |
| US-20090118243-A1 | Compositions and methods for the treatment of ophthalmic conditions | RESOLVYX PHARMACEUTICALS, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090118243-A1 | Compositions and methods for the treatment of ophthalmic conditions | RESOLVYX PHARMACEUTICALS, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| WO-2009051670-A2 | OXYLIPIN COMPOUNDS FOR THE TREATMENT OF OPHTHALMIC CONDITIONS | RESOLVYX PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| WO-2008057283-A9 | USE OF RESOLVINS FOR INHIBITION OF BONE LOSS | RESOLVYX PHARMACEUTICALS INC (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20080161274-A1 | Compounds and methods for inhibition of bone loss | RESOLVYX PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161275-A1 | Compositions and methods for the treatment of inflammatory disease | RESOLVYX PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161274-A1 | Compounds and methods for inhibition of bone loss | RESOLVYX PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161275-A1 | Compositions and methods for the treatment of inflammatory disease | RESOLVYX PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2008070129-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE | RESOLVYX PHARMACEUTICALS, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008057283-A2 | USE OF RESOLVINS FOR INHIBITION OF BONE LOSS | RESOLVYX PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161275-A1 | Compositions and methods for the treatment of inflammatory disease | ALOX15B, ALOX12, ALOX15 | OXER1 140/4885ALDH1A1 1031/4885PPARG 243/4885 |
| US-20150165048-A1 | TOPICAL FORMULATIONS AND USES THEREOF | LIPA, MGLL, LIPC | OXER1 2251/4885ALDH1A1 285/4885PPARG 133/4885 |
| US-20090118243-A1 | Compositions and methods for the treatment of ophthalmic conditions | ALOX15B, ALOX5, ALOX12 | OXER1 112/4885ALDH1A1 798/4885PPARG 425/4885 |
| US-20080161274-A1 | Compounds and methods for inhibition of bone loss | ALOX15B, ALOX5, ALOX12 | OXER1 416/4885ALDH1A1 3157/4885PPARG 151/4885 |
| US-20140275247-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | ALOX15B, ALOX5, ALOX12 | OXER1 273/4885ALDH1A1 2449/4885PPARG 111/4885 |
| US-20160256521-A1 | TOPICAL FORMULATIONS AND USES THEREOF | LIPA, MGLL, LIPC | OXER1 2251/4885ALDH1A1 285/4885PPARG 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.